Search for Terms or Answers
Dr. Cush reviews best reasons to go to ACR annually, but also the best way to learn ACR26 content this year.
For my take on what has happened with zola-cel safety and what it tells us about interpreting CAR-T safety in general, check out my #ACR26 article @RheumNow: https://t.co/mGZmOsoE8o
BREAKING: Reports that Novartis still working on IEC-HS investigation after rap-cel CAR-T deaths. Georg Schett calls lack of details "very sad" & has submitted commentary to @NEJM (with Carl June, CAR-T inventor) to discuss it https://t.co/Tn2svGi0BP #ACR26 @RheumNow https://t.co/5ZJ8pGCQg7
Interpreting CAR-T safety: lessons from zola-cel so far While there is plenty to watch this ACR in the maturing CAR-T space, one of the big global stories in the second half of 2026 has been about zola-cel and the pause in the Breakfree program. https://t.co/hhipJBLr2Y https://t.co/KLjhJHrvj3
CAR-T in SLE 2026 -Autologous CART: likely to achieve target faster (shorter time for SLEDAI/DORIS) -CD19-vs dual target (BCMA): no significant difference on SLEDAI -Pt w/ LN at baseline had steeper decline on SLEDAI -SAFETY: 64% of pts had CRS manageable (low grade) 95% of https://t.co/XyMOeoSpPL
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.